Overview

Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this protocol is to determine the efficacy of EGb 761 120 mg bid versus placebo in patients suffering from Friedreich Ataxia
Phase:
Phase 2
Details
Lead Sponsor:
Ipsen